Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long‐terminal repeats

Haemophilia - Tập 9 Số 1 - Trang 94-103 - 2003
An Van Damme1, Marinee Chuah1, Francesco Dell’Accio2, Cosimo De Bari2, Frank P. Luyten2, Peter Carmeliet1, Thierry VandenDriessche1
1Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology; and
2Laboratory for Skeletal Development and Joint Disorders, University of Leuven, Leuven, Belgium

Tóm tắt

Summary. Bone marrow (BM) cells are attractive target cells for ex vivo gene therapy of genetic diseases, including haemophilia A. However, BM‐derived haematopoietic stem/progenitor cells (HSCs) transduced with factor VIII (FVIII) retroviral vectors, failed to express FVIII in vivo. To overcome the limitations of HSCs for haemophilia gene therapy, BM‐derived mesenchymal cells were explored as alternative target cells. The BM mesenchymal cell population contains self‐renewing mesenchymal stem/progenitor cells that give rise to different mesenchymal lineages and have been used safely in phase I gene‐marking trials. Human BM mesenchymal cells were transduced in vitro with an improved retroviral vector encoding a human B‐domain deleted FVIII (hFVIIIΔB) cDNA (MND‐MFG‐hFVIIIΔB). This vector contains multiple modifications in the cis‐acting elements within the MoMLV long‐terminal repeats (LTR) that prevent the binding of repressive transcription factors. These modifications were previously shown to increase and prolong gene expression in embryonic stem (ES) cells and HSCs. Transduction of BM mesenchymal cells with the MND‐MFG‐hFVIIIΔB retroviral vector resulted in high levels of functional human FVIII in vitro, ranging between 300 ± 50 SD and 700 ± 100 SD mU per 106 cells per 24 h. Following xenografting of the transduced human BM cells into immunodeficient NOD‐SCID mice, therapeutic hFVIII levels of 12 ± 10 ng mL−1 were detected in the plasma. Polymerase chain reaction analysis demonstrated long‐term engraftment (>3 months) of the human BM mesenchymal cells. The long‐term persistence of BM mesenchymal cells in the absence of myelo‐ablative conditioning and the therapeutic FVIII levels in vivo underscore the potential usefulness of BM‐derived mesenchymal cells for haemophilia gene therapy, as opposed to BM‐derived HSCs. Despite the modifications of the MoMLV LTR, FVIII expression declined, which coincided with a decrease in FVIII mRNA transcription levels, indicating that the salutary effect of the LTR modification on transgene expression is not universally applicable to all cell types.

Từ khóa


Tài liệu tham khảo

10.1182/blood.V95.5.1594.005k34_1594_1599

10.1182/blood.V97.10.3311

10.1006/mthe.2001.0264

10.1182/blood.V95.3.820.003k32_820_828

Zhang WW, 1999, Development and application of a minimal‐adenoviral vector system for gene therapy of hemophilia A, Thromb Haemost, 82, 562, 10.1055/s-0037-1615881

10.1182/blood.V96.3.1173.015k34_1173_1176

10.1056/NEJM200106073442301

10.1073/pnas.95.10.5734

Hoeben RC, 1992, Toward gene therapy in haemophilia A: retrovirus‐mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells, Thromb Haemost, 67, 341, 10.1055/s-0038-1648444

10.2174/1566523024605645

10.1038/nature00870

10.1182/blood.V98.9.2615

10.1089/hum.1998.9.3-353

Drize NJ, 1992, Gene therapy model for stromal precursor cells of hematopoietic microenvironment, Leukemia, 6, 174S

10.1111/j.1600-0609.1995.tb00701.x

Nolta JA, 1994, Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin‐3: analysis of gene transduction of long‐lived progenitors, Blood, 83, 3041, 10.1182/blood.V83.10.3041.3041

10.1073/pnas.132252399

10.1073/pnas.91.7.2567

Challita P‐M, 1995, Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells, J Virol, 69, 748, 10.1128/jvi.69.2.748-755.1995

Robbins PB, 1997, Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells, J Virol, 71, 9466, 10.1128/jvi.71.12.9466-9474.1997

10.1073/pnas.95.17.10182

10.1089/10430340050015626

10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P

10.1089/hum.1995.6.11-1363

10.1073/pnas.96.18.10379

10.1007/BF02509499

Prince VE, 1991, Derivatives of Moloney Murine Sarcoma Virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional Sp1 binding site, J Virol, 65, 1803, 10.1128/jvi.65.4.1803-1811.1991

10.1128/MCB.12.1.38

10.1128/MCB.9.2.739

Grez M, 1991, A single point mutation activates the moloney murine leukemia virus long terminal repeat in embryonal stem cells, J Virol, 65, 4691, 10.1128/jvi.65.9.4691-4698.1991

10.4049/jimmunol.154.1.180

10.1002/jgm.248

10.1128/MCB.16.8.4264

Hoeben RC, 1995, Expression of the blood‐clotting factor‐VIII cDNA is repressed by a transcriptional silencer located in its coding region, Blood, 85, 2447, 10.1182/blood.V85.9.2447.bloodjournal8592447

10.1089/hum.1995.6.4-469

10.1089/hum.1993.4.3-259

10.1073/pnas.92.4.1023

10.1074/jbc.274.28.19587

10.1182/blood.V99.2.457

Thông tin
Thông tin xuất bản

Haemophilia

Tập 9 Số 1

94-103

Thông tin tác giả